Engineered immune cells target Tough-to-Treat blood cancer
NCT ID NCT07288879
Summary
This study is testing a new personalized cell therapy for adults with an aggressive type of lymphoma (DLBCL) that has come back or stopped responding to at least two prior treatments. Doctors will collect a patient's own immune cells, genetically modify them in a lab to better recognize and attack the cancer, and then infuse them back into the patient. The main goal is to see if this one-time treatment is safe and can shrink or eliminate the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Juntendo University Hospital
NOT_YET_RECRUITINGTokyo, 113-8431, Japan
-
Keio University Hospital
NOT_YET_RECRUITINGTokyo, 160-8582, Japan
-
National Cancer Center Hospital
RECRUITINGTokyo, 104-0045, Japan
-
Tokyo Metropolitan Komagome Hospital
RECRUITINGTokyo, 113-8677, Japan
-
Toranomon Hospital
NOT_YET_RECRUITINGTokyo, 105-8470, Japan
Conditions
Explore the condition pages connected to this study.